Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 15;7(4):ofaa130.
doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Affiliations
Free PMC article
Review

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Katelyn A Pastick et al. Open Forum Infect Dis. .
Free PMC article

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

Keywords: COVID-19; Hydroxychloroquine; SARS-CoV-2; chloroquine; clinical trials; coronavirus.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report - 75. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200401-sitrep-72-covid-19.pdf?sfvrsn=3dd8971b_2. Accessed 4 April 2020.
    1. NIH U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ Accessed 4 April 2020.
    1. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020; In Press. - PMC - PubMed
    1. Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013; 35:434–42. - PubMed
    1. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42:145–53. - PMC - PubMed
Feedback